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Objective. To better understand attributes of ART-associated HIV-induced T-cell responses that might be therapeutically harnessed.
Methods. CD8+ T-cell responses were evaluated in some HIV-1 chronically infected participants of the fixed duration STI substudy
of the DART trial. Magnitudes, breadths, and functionality of IFN-γ and Perforin responses were compared in STI (n = 42)
and continuous treatment (CT) (n = 46) before and after a single STI cycle when the DART STI trial was stopped early due to
inferior clinical outcome in STI participants. Results. STI and CT had comparable magnitudes and breadths of monofunctional
CD8+IFNγ+ and CD8+Perforin+ responses. However, STI was associated with significant decline in breadth of bi-functional
(CD8+IFNγ+Perforin+) responses; P = .02, Mann-Whitney test. Conclusions. STI in individuals initiated onto ART at <200 CD4+
T-cell counts/μl significantly reduced occurrence of bifunctional CD8+IFNγ+/Perforin+ responses. These data add to others that
found no evidence to support STI as a strategy to improve HIV-specific immunity during ART.
1. Introduction
Previous studies correlated ART uptake with diminution
of HIV-specific responses [1–3], whilst others linked it
with restoration of these responses [4–6]. Uptake of ART
has also presented challenges such as high pill burden,
drug resistance, cost, and drug-induced toxicities. Structured
treatment interruption has been widely evaluated in an
eﬀort to decrease costs and side eﬀects of ART uptake
and to investigate associated immunological and clinical
outcomes. Consequently, several large clinical trials have
explored whether minimizing dose [7–10], or duration of
ART exposure [11, 12] and therefore, their toxic eﬀects would
be beneficial.
The cellular arm of the immune system has been
associated with protection from HIV disease progression
[13]. This has been remarkably demonstrated in CD8+ T-
cell depletion studies in macaque models [14–16] as well
as in acute infection studies correlating the emergence of
virus specific CD8+ T cells with control of viraemia [17]. In
addition, correlation between slow HIV-1 disease progres-
sion and protective HLA allele-induced CTL responses has
been observed [18], and associations between viral escape
in targeted HIV epitopes and elevation of plasma viral
loads have been demonstrated [19]. Despite this body of
evidence, consistent quantitative and qualitative correlates of
protection remain elusive. Evaluations comparing breadths
and magnitudes of CD8+ T-cell responses in infected persons
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have sometimes failed to show any association between these
parameters and viral load [18, 20, 21]. Moreover, despite
the preservation and increase in HIV-specific CD8+ T-cell
responses in individuals who initiated ART during acute
infection [22, 23], attempts to boost T-cell responses, for
example, through autovaccination during ART interruptions
in chronic HIV infection, have proven disappointing [9, 19,
24–26].
The potential for STI to boost HIV-specific immunity
through controlled autologous virus exposure has been
previously evaluated in chronically infected HIV patients
[27–29] and has been reviewed in [30]. In some of these
studies, CD8+ T-cell responses were boosted by re-exposure
to autologous virus, although increases in virus-induced
CD4+ T-cell responses were transient. Marked interpatient
heterogeneity and small cohort sizes in previous studies
yielded inconclusive and inconsistent results [26, 31–33].
While functional attributes of CD8+ T-cell responses have
accounted for diﬀerential disease outcomes observed in
chronic HIV infection [34–36], the extents to which diﬀer-
ences in CD8+ T-cell functionality occur during STI remain
unclear.
In this study, we evaluated a proportion of DART
trial participants [37] who enrolled into the DART STI
substudy [38] in order to better understand the possible
immunological outcomes of STI in individuals initiated onto
ART with advanced HIV disease (<200 CD4+ T cells/μL).
Participants randomized to STI or to continuous treatment
(CT) at one clinical centre (MRC/UVRI, Entebbe, Uganda)
were compared in order to reevaluate the hypothesis that
STI would allow regeneration of HIV-specific responses
through cyclical viral antigen exposure whilst CT would not
allow viral antigen exposure and consequent regeneration of
immune responses.
2. Methods
2.1. Study Design and Population. The multisite DART
main trial (ISCRTN 13968779-DART) [37] recruited 3316
chronically HIV-infected, ART-naı¨ve adults (except for ART
exposure during pregnancy for prevention of mother-to-
child transmission) with WHO stage 2, stage 3, or stage
4 symptomatic disease and CD4+ counts ≤200 cells/μL at
screening to primarily compare clinical driven monitoring
with laboratory monitoring plus clinical monitoring as
strategies of ART delivery. A fixed duration STI random-
ization substudy (12 weeks on ART and 12 weeks oﬀ
ART per STI cycle) was nested within the DART trial to
primarily evaluate whether STI was clinically noninferior to
continuous treatment. Participants, who had attained ≥300
CD4+ T cells/μL by 48 or 72 weeks after DART trial entry,
underwent a second randomization at 52 or 76 weeks to
either STI (n = 408) or CT (n = 405), with intention to
follow up 8 STI cycles. At the time of STI/CT randomization,
we consecutively recruited 60 STI and 60 CT participants
from each arm. Heparinised blood (10 mls) was collected at
the beginning and end of one STI cycle corresponding to
week 0 and week 12, respectively. By the time the trial was
stopped early following a DSMC review, 42 STI and 46 CT
participants had completed one full STI cycle. None of the 88
evaluated subjects (60 women) received any prior exposure
to ART even for prevention of mother-to-child transmission.
2.2. CD4+ T-Cell Count Quantification and Timing of T-
Cell Response Evaluations. Scheduled 12 weekly CD4+ T-cell
counts were performed within the main DART trial using
FACScount (Becton Dickinson) according to manufacturer’s
protocols. The beginning of the first STI/CT randomization
cycle was timed to occur 4 weeks after the last prerandom-
ization CD4+ count. The next CD4+ count occurred 8 weeks
after the start of the cycle and 8 weeks after restarting ART
in the STI group. To evaluate HIV-induced CD8+ T-cell
responses, additional blood specimens were collected in both
groups at the beginning of an STI cycle and when ART was
restarted in the STI group.
2.3. HIV Peptides and Preparation of Pools. Uganda is
predominantly infected with HIV-1 clades A and D as well as
recombinants of these [18, 39–41]. We therefore attempted
to work with peptide pools that were matching these
strains as much as possible. Peptides were obtained through
the National Institute of Health, AIDS Research Reference
Reagent programe (https://www.aidsreagent.org/Index.cfm).
Unfortunately, peptides available from this source were only
representative of clade B with the exception of peptides corre-
sponding to the Gag region which matched the strains found
in our study population. Individual peptides consisted of 20-
mer peptides overlapping by 11 amino acids and spanning
the HIV-1 consensus clade A (92UG037) and D (94UG114)
Gag sequences, as well as 15-mer peptides overlapping by
11 amino acids spanning the HIV-1 clade B Nef, Tat, Vif,
Rev, Vpr, Vpu, and Pol consensus sequences. Individual
peptides were grouped together into pools according to HIV
protein. Each individual peptide within a pool was used at a
final concentration of 2 μg/ml. Due to limitations in blood
volume, it was not possible to map individual responding
T-cell epitopes; consequently, CD8+ T-cell responses to
complete HIV-1 protein pools are presented.
2.4. Intracellular Cytokine Staining Procedure. Activation and
processing of peripheral blood mononuclear cells (PBMCs)
for intracellular cytokine staining analysis was performed as
previously described [42]. Briefly, activation reagents (HIV
peptide pools and 1 μg/mL costimulatory CD28 and CD49d
antibodies (BD Biosciences)) were added to 1 mL of fresh
whole heparinised blood and incubated at 37◦C, in a 5% CO2
in air atmosphere for 1 hour, followed by further 5 hours in
the presence of a secretion inhibitor (Golgi Plug, 10 μg/ml,
BD Biosciences). Red blood cells were subsequently lysed
with FACS lysis solution (BD Biosciences). The PBMCs were
fixed and permeabilised with FACS permeabilising buﬀer
(BD Biosciences) according to the manufacturer’s protocol
and then simultaneously stained for 1 hour in the dark with
surface antibodies CD3-FITC, CD8+-PerCP and intracellular
antibodies IFN-γ-APC and Perforin-PE (BD Biosciences)
at room temperature. Stained cells were washed and fixed
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with Cellfix (BD Biosciences). At least 200,000 PBMCs were
acquired on a FACSCalibur flow cytometer (BD Biosciences).
Negative controls (backgrounds) were autologous PBMCs
that were not stimulated with peptides but had otherwise
been treated identically. Positive controls were specimens
that had been stimulated with 10 μL of 1 μg/μL of Staphy-
lococcal Enterotoxin B (SEB). Flow cytometry data was
analysed using CellQuest (BD Biosciences). Criterion for
evaluating positive responses was ≥0.03% of CD8+ T cells
responding to any of the HIV peptide pools after subtracting
the background cytokine production. Response to the two
Gag pools (clade A and D) was evaluated collectively as the
mean Gag response. Monofunctional T cells were defined as
those secreting either IFN-γ or Perforin alone; bifunctional T
cells were defined as cells that simultaneously released both
Perforin and IFN-γ. Breadth of response was defined as the
number of HIV protein pools targeted by each participant.
The frequency of HIV-induced response was defined as the
proportion (%) of CD8+ T cells inducing HIV-specific IFN-γ
or Perforin responses or both. The frequency of responders
was defined as the proportion of participants in which HIV-
specific T-cell responses were induced.
2.5. Statistical Analysis. Medians and interquartile ranges
(IQR) were used for all summary presentations of CD4+ T-
cell counts and T-cell responses. Kruskal-Wallis rank and
Mann-Whitney tests were used to compare medians. Propor-
tions were compared using Pearson’s chi-square test. Median
alterations in response for each patient were compared by
evaluating the increase or decrease in CD8+ T-cell response
at the beginning and end of a 12-week cycle. This approach
provided a more powerful test of diﬀerences between CT and
STI, since it allowed each patient to act as their own control
therefore reducing variability. Graph Pad 5.0 and Excel were
used for graphical presentations of the data. All statistical
analyses were performed using Stata v8.0 (Stata Corp, Texas).
3. Results
3.1. Study Population and Baseline Characteristics. Of the
120 participants recruited into this substudy, 88 subjects
(42 STI and 46 CT) had completed one cycle of STI
by the time the Trial Steering Committee (TSC) followed
the recommendation of the DSMC to terminate the STI
trial due to observed inferior clinical outcomes among
participants randomized to the STI group. Similar to the
overall demographics seen in the main DART trial, our study
evaluated significantly more females (n = 60) than males
(n = 28). There was no significant diﬀerence in the median
age of CT (38; 33–44 years) and STI (38; 32–44 years)
subjects. The proportion of STI and CT subjects with pre-
STI/CT randomization ART exposure duration of either 52
(28/46 versus 22/42, resp.) or 76 weeks (18/46 versus 20/42,
resp.) was also comparable.
3.2. Comparison of CD4+ T-Cell Counts. In the current study
subjects, the median CD4+ counts at ART initiation within
the main DART trial were comparable between STI (124;
IQR 87–177 CD4+ T cells/μL) and CT subjects (129; IQR 77–
159 CD4+ T cells/μL). Inline with the findings of the main
DART STI trial [38], we did not find any diﬀerence between
CD4+ T-cell counts of STI (391; 334–449 cells/μL) and CT
subjects (391; 333–449 cells/μL) at STI/CT randomization.
Additionally, CD4+ T-cell counts were comparable among
subjects that were randomized after 52 weeks (397; 334–
457 cells/μL) or 76 weeks of ART initiation (385; 330–
434 cells/μL). These data suggest that an additional 24 weeks
of ART exposure prior to STI/CT randomization did not
significantly influence the CD4+ T-cell counts anymore at
this stage.
3.3. Frequency of HIV-Specific CD8+ T-Cell Responses at
STI/CT Randomization. We evaluated the frequency of HIV
Gag (clade A and D), Nef, Tat, Vif, Rev, Vpr, and Vpu
(all clade B)-induced T-cell responses as the proportion of
subjects with detectable virus-specific CD8+ T-cell IFN-γ
or Perforin. Overall, HIV-specific CD8+ T-cell responses
were detected against all the seven evaluated HIV proteins
as follows: Gag- (85%), Nef- (67%), Tat- (51%), Vpr-
(53%), Vpu- (58%), Rev- (52%) and Vif- (48%). At STI/CT
randomization, 99% of the participants had the potential
to induce IFN-γ while 31% completely lacked the intrinsic
potential to induce Perforin (as evaluated by stimulation
with SEB) (Figures 1(a) and 1(b), resp.)
We then evaluated the relationship between the dura-
tion of ART uptake before STI/CT randomization, CD4+
count at ART initiation and the frequency of virus-specific
CD8+ T-cell responses at STI/CT randomization. Both HIV-
specific IFN-γ (Figure 1(c)) and Perforin T-cell responses
(Figure 1(d)) did not significantly diﬀer between participants
who received ART for 52 or 76 weeks. Similarly, there was
no correlation between the CD4+ count at ART initiation
and the frequency of virus-induced T-cell responses (data
not shown). Taken together, these findings suggest that the
additional 24 weeks of ART in individuals who underwent
STI/CT randomization at 76 weeks did not significantly
modify the proportion of subjects with detectable HIV-
induced CD8+ T-cell recognition.
3.4. Breadth of HIV-Induced CD8+ T-Cell Responses at
STI/CT Randomization. Breadth of response was defined
as the number of HIV protein pools targeted by each
subject. Overall, breadths of CD8+IFNγ+, CD8+Perforin+
and CD8+IFNγ+Perforin+ at STI/CT randomization lacked
correlation with the nadir CD4+ count and did not diﬀer
in subjects that took ART for either 52 or 76 weeks
before STI/CT randomization (Figure 2). These data suggest
that the additional 24 weeks of ART uptake before STI
randomization did not influence the breadth of virus-specific
T-cell responses.
3.5. Magnitude of HIV-Induced T-Cell Responses at STI/CT
Randomization. Magnitude of T-cell response was defined as
the proportion (%) of CD3+CD8+ T cells inducing release
of either IFN-γ, Perforin or both, following stimulation
with HIV-1 Gag, Nef, Tat, Vpr, Vpu, Rev and Vif peptide
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Figure 1: HIV-specific CD8+ T-cell responses at STI/CT randomization. This figure compares the proportions (%) of participants (n = 88)
inducing (a) HIV-specific IFN-γ or (b) Perforin responses at the time point of STI/CT randomization and proportions of participants
inducing (c) HIV-specific IFN-γ or (d) Perforin responses at STI/CT randomization initiated 52 or 76 weeks after ART.
pools. Gag data is presented as the average of the two Gag
pools. At STI/CT randomization, the inherent magnitude of
T-cell responses as evaluated using Staphylococcal Entero-
toxin B (SEB) was significantly lower for Perforin (0; 0–
0.12% CD3+CD8+ T cells) compared to IFN-γ (5; 3–9%
CD3+CD8+ T cells), respectively; P < .0001, Mann-Whitney
test. Thus, it may be seen that HIV-1-specific CD8+ T-cell
responses in this cohort were mostly comprised of IFN-γ-
secreting cells at the time point of STI/CT randomization.
We therefore used the IFN-γ data to evaluate the relation-
ship between STI and the pattern of virus-specific T-cell
recognition. Overall, Nef and Gag (mean of the two Gag
pools) induced significantly higher magnitude of CD8+ T-
cell responses than Tat, Vpr, Vpu, Rev, and Vif in both CT
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Figure 2: Relationship between breadth of HIV-specific CD8+ T-cell recognition at STI/CT randomization and the duration of pre-ART
randomization. This figure evaluates whether ART uptake for either 52 weeks or 76 weeks preceding randomization had any influence on
the breadths of HIV-specific (a) CD8+IFNγ+, (b) CD8+Perforin+, or (c) CD8+IFNγ+Perforin+ T-cell responses. Individual HIV peptides
were grouped together in pools according to HIV protein. HIV-specific T-cell recognition was evaluated against these pools that were based
on consensus sequences of HIV-1 Gag clades A (92UG037) and D (94UG114); and consensus sequences of HIV-1 clade B (Nef, Tat, Vif, Rev,
Vpr, Vpu, and Pol). HIV-specific responses to Gag (clades A and D) were considered concomitantly. Breadth was defined as the number of
HIV protein pools recognised per individual. Horizontal bars represent medians and interquartile ranges.
and STI participants; magnitudes of Gag- and Nef-induced
responses did not significantly diﬀer (Figures 3(a) and 3(b)).
3.6. Magnitudes after One STI Cycle (12-Week On/12-Week
Oﬀ). The median change in Nef-, Tat-, Vpr-, Vpu-, Rev-,
and Vif-induced IFN-γ magnitudes remained comparable
among CT and STI subjects although there was significant
increase in magnitude of Gag-induced IFN-γ (Figure 3(c)).
Despite the apparent improvement in magnitudes of Gag-
induced IFN-γin STI subjects, the magnitude of Perforin
responses remained significantly lower compared to IFN-γ
even after 12 weeks of CT or STI, and the ability (proportion
of individuals) of the STI arm to induce simultaneously
release of both IFN-γ and Perforin did not improve even
for Gag (data not shown). Taken together, these data suggest
a preexisting functional impairment of CD8+ T cells in
this cohort, mainly characterised by diminution of Perforin-
inducing potential, which remained unchanged after 12
weeks of STI.
3.7. Breadths after One STI Cycle (12-Week On/12-Week Oﬀ).
We evaluated the relationship between one STI cycle and
the breadth of HIV-induced CD8+ T-cell responses (number
of HIV proteins recognised per subject). Recognition of
the two Gag pools was analyzed concomitantly to represent
the average response to the Gag protein. Median change in
breadth was defined as the increase or decrease in number of
HIV pools recognised after completing one STI cycle. After
12 weeks of STI or CT, the median change in breadth of
CD8+IFNγ+ (Figure 4(a)) and CD8+Perforin+ (Figure 4(b))
did not significantly diﬀer between STI and CT participants.
However, STI was associated with a significant reduction
in breadth of bifunctional CD8+IFNγ−Perforin+ responses
(median −1, IQR 0 to −3.3 protein pools) compared to CT,
(median 0, IQR−2.0 to 3.0 HIV protein pools) (Figure 4(c)).
Similarly, there was no diﬀerence in the breadth of mono-
functional IFN-γ responses targeted (Figures 4(d) and 4(e)).
However, 12 weeks of STI resulted in significantly lower
bifunctional T-cell responses, (median 1, IQR 0–3 protein
pools) compared to a similar timeframe on continuous
treatment (median 3, IQR 1–4 protein pools); P = .027
(Figure 4(f)), Mann-Whitney test. These data suggest that
STI was associated with degeneration rather than restoration
of functional CD8+ T-cell responses in this cohort.
4. Discussion
Better understanding of HIV-induced CD8+ T-cell responses
in chronic HIV-1 infection may be important for the devel-
opment of preventive or therapeutic approaches designed
to enhance T-cell-mediated immunity. In this study, we
used structured treatment interruption that was initiated
within the DART trial [38] as a model to reevaluate the
hypothesis that STI would allow for regeneration of HIV-
specific responses through cyclical viral antigen exposure.
The DART cohort diﬀered from previous studies that
assessed individuals initiated on ART at an earlier HIV
disease state [8, 10, 43]. The principle findings of this study
were firstly that magnitudes of CD8+ T-cell responses did
not significantly diﬀer following STI or CT for an identical
timeframe, secondly that breadths of monofunctional CD8+
T-cell responses were comparable between STI and CT, and
thirdly that STI was apparently associated with significant
loss of bifunctional CD8+ T-cell responses.
Because the overall potential to induce Perforin was
apparently impaired in this cohort initiated on ART at
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Figure 3: Magnitudes of CD8+ T-cell responses associated with STI. This figure compares the median magnitudes of HIV-induced CD8+
T-cell IFN-γ responses in (a) STI and CT participants after one cycle of STI or matching time on CT. Bars represent medians, while error
bars represent interquartile ranges. The shaded areas represent HIV proteins that induced significantly lower magnitudes of CD8+IFN-γ+
than Gag or Nef. (c) illustrates the median change in magnitudes of HIV-specific IFN-γ responses after one cycle of STI or matching time
on CT. Horizontal bars represent medians.
around 125 (85–173) CD4+ T cells/μL, we used the IFN-γ
data to evaluate the relationship between STI and the profile
of CD8+ T-cell responses. Overall, Gag and Nef induced
significantly higher magnitude of IFN-γ responses than other
HIV proteins tested at STI/CT randomization in both STI
and CT participants; this finding was consistent with others
that reported relative immunodominance of Gag and Nef
in this and other populations [17, 18]. However, there were
some limitations related to the reagents used to evaluate
CD8+ T-cell responses, and the Gag results need to be
interpreted with caution. The peptides used to stimulate
CD8+ T cells matched the infecting HIV strains only in the
Gag region, whereas clade B peptides were used to evaluate
responses to the other proteins. Consequently, virus-specific
CD8+ T-cell responses to other HIV proteins may not have
been detected as eﬃciently as responses to Gag, where the
infecting viral sequences were better represented. Indeed,
several studies have shown that interclade cross-reactivity
response rates tend to be lower than clade-specific responses
[18, 44, 45] and that use of variant sequences can result in
reduced T-cell recognition.
HIV-specific T-cell responses are common in infected
adults, become progressively dysfunctional during chronic
virus persistence, and exhibit rapid decay during ART
uptake [1, 46–48]. Previous studies suggested that several
functional attributes of HIV-specific CD8+ T cells influence
the diﬀerential disease outcome in chronic infection [34–
36, 49, 50]. Continuous use of potent ART has been shown
to significantly suppress viral replication [51–53], thereby
potentially allowing for limited T-cell functional restoration.
In this cohort, STI significantly correlated with diminution
of CD8+IFNγ+Perforin+ bifunctional T cells. This was
consistent with previous reports of STI-associated functional
impairment of T cells [19]; attribution of the prognostic
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Figure 4: Breadths of CD8+ T-cell responses after 12 weeks of STI and matching time point on CT. Study participants were evaluated for
CD8+ T-cell responses to complete peptide pools corresponding to Gag, Nef, Tat, Vpr, Vpu, Rev and Vif HIV proteins. Response to the
two Gag pools was analysed concomitantly to represent response to the Gag protein. Breadth of CD8+ T-cell response was defined as the
number of HIV pools recognised by an individual. Median change in breadth was defined as the increase or decrease in number of pools
recognised. Positive readouts indicate increase while negative readouts indicate decrease. The figure demonstrates changes in the breadth
of CD8+IFNγ+ (a), CD8+Perforin+ (b) and CD8+IFNγ+Perforin+, (c) responses among CT and STI participants; and compares the median
number of peptide pools targeted with the induction of CD8+IFNγ+ (d), CD8+Perforin+ (e), and CD8+IFNγ+Perforin+ (f) at the end of one
STI cycle. Horizontal lines represent medians.
outcomes of STI to a defined virus-specific CD8+ T-cell
functional profile [50] and to findings that indicated that
continued use of potent ART could defer this impairment
[46, 54].
In this study, an extra 24 weeks of therapy in individuals
that were randomized to STI or CT at 76 weeks did not
result in any apparent change in profile of HIV-induced
CD8+ T-cell responses when compared to those that were
randomized at 52 weeks. Consequently, these data suggest
that the observed diﬀerence in breadth of the bifunctional
CD8+ T cell responses may be possibly attributed to STI
rather than to the restoration of functionality by continued
treatment. These data collectively suggest an STI-associated
impairment of CD8+ T-cell functionality and that the quality
rather than the quantity of the HIV-specific CD8+ T-cell
responses correlated with the dynamics of STI.
There were other limitations to this study. First of all, we
evaluated a population that was initiated onto ART at a very
advanced stage of HIV disease potentially masking possible
positive eﬀect that others observed in individuals who
initiated ART much earlier in disease [55, 56]. The benefits
and risks of antiretroviral therapy can vary considerably with
stage of disease, mainly due to irreversible destruction of
the immune system that occurs as HIV infection progresses.
Treatment during acute HIV infection may preserve and
reconstitute HIV-specific immune function. Alternatively,
the primary goal of late-stage disease treatment is to
control viral replication leading to decreased morbidity and
increased survival. While our sample size was not big enough
to evaluate the eﬀect of disease stage, exploration of the data
revealed no correlation between the CD8+ T-cell responses
and the original CD4+ count before ART initiation. Secondly,
we evaluated only one cycle of STI; consequently, we could
not extrapolate on possible longer-term eﬀects of STI that
have been reported in studies that used a longitudinal
approach to evaluate several STI cycles [31]. Lastly, this study
was limited to collect 10 mls of blood from each subject
at each study visit. Subsequently, individual peptides were
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grouped according to HIV protein and evaluated as pools. As
a result, it was not possible to map individual responding T-
cell epitopes in order to determine whether it was responses
specific for a particular epitope that disappeared during an
STI or all epitopes were aﬀected equally.
In summary, the current study found no evidence to
support the hypothesis that STI would enhance regeneration
of HIV-induced T-cell responses in individuals starting ART
with advanced HIV disease state. Instead, our findings are
inline with previous reports that indicated ART-associated
improvement of CD8+ T-cell functional markers [52, 57],
preferential destruction of HIV-infected CD4+ T cells during
treatment interruptions [58], and viral burden-induced
deterioration of the quality of CD8+ T-cell response even
when HIV-specific IFN-γ responses were still apparent [59].
This study found no evidence to support STI as a strategy for
ART delivery in African patients starting therapy with CD4+
counts <200 cells/μL.
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